These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 26595550)
1. Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer. Lopez-Siles M; Martinez-Medina M; Surís-Valls R; Aldeguer X; Sabat-Mir M; Duncan SH; Flint HJ; Garcia-Gil LJ Inflamm Bowel Dis; 2016 Jan; 22(1):28-41. PubMed ID: 26595550 [TBL] [Abstract][Full Text] [Related]
2. Alterations in the Abundance and Co-occurrence of Lopez-Siles M; Enrich-Capó N; Aldeguer X; Sabat-Mir M; Duncan SH; Garcia-Gil LJ; Martinez-Medina M Front Cell Infect Microbiol; 2018; 8():281. PubMed ID: 30245977 [No Abstract] [Full Text] [Related]
3. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Lopez-Siles M; Martinez-Medina M; Busquets D; Sabat-Mir M; Duncan SH; Flint HJ; Aldeguer X; Garcia-Gil LJ Int J Med Microbiol; 2014 May; 304(3-4):464-75. PubMed ID: 24713205 [TBL] [Abstract][Full Text] [Related]
4. Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease. Lopez-Siles M; Martinez-Medina M; Abellà C; Busquets D; Sabat-Mir M; Duncan SH; Aldeguer X; Flint HJ; Garcia-Gil LJ Appl Environ Microbiol; 2015 Nov; 81(21):7582-92. PubMed ID: 26296733 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification. Lopez-Siles M; Aldeguer X; Sabat-Mir M; Serra-Pagès M; Duncan SH; Flint HJ; Garcia-Gil LJ; Martinez-Medina M World J Gastrointest Pathophysiol; 2020 May; 11(3):64-77. PubMed ID: 32435523 [TBL] [Abstract][Full Text] [Related]
6. Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. Eppinga H; Sperna Weiland CJ; Thio HB; van der Woude CJ; Nijsten TE; Peppelenbosch MP; Konstantinov SR J Crohns Colitis; 2016 Sep; 10(9):1067-75. PubMed ID: 26971052 [TBL] [Abstract][Full Text] [Related]
8. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Varela E; Manichanh C; Gallart M; Torrejón A; Borruel N; Casellas F; Guarner F; Antolin M Aliment Pharmacol Ther; 2013 Jul; 38(2):151-61. PubMed ID: 23725320 [TBL] [Abstract][Full Text] [Related]
9. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. Lopez-Siles M; Duncan SH; Garcia-Gil LJ; Martinez-Medina M ISME J; 2017 Apr; 11(4):841-852. PubMed ID: 28045459 [TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease. Zhao H; Xu H; Chen S; He J; Zhou Y; Nie Y J Gastroenterol Hepatol; 2021 Feb; 36(2):320-328. PubMed ID: 32815163 [TBL] [Abstract][Full Text] [Related]
11. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. Fujimoto T; Imaeda H; Takahashi K; Kasumi E; Bamba S; Fujiyama Y; Andoh A J Gastroenterol Hepatol; 2013 Apr; 28(4):613-9. PubMed ID: 23216550 [TBL] [Abstract][Full Text] [Related]
12. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Willing B; Halfvarson J; Dicksved J; Rosenquist M; Järnerot G; Engstrand L; Tysk C; Jansson JK Inflamm Bowel Dis; 2009 May; 15(5):653-60. PubMed ID: 19023901 [TBL] [Abstract][Full Text] [Related]
13. First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening. Grobbee EJ; Lam SY; Fuhler GM; Blakaj B; Konstantinov SR; Bruno MJ; Peppelenbosch MP; Kuipers EJ; Spaander MC United European Gastroenterol J; 2020 Apr; 8(3):293-302. PubMed ID: 32213018 [TBL] [Abstract][Full Text] [Related]
14. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Lopez-Siles M; Khan TM; Duncan SH; Harmsen HJ; Garcia-Gil LJ; Flint HJ Appl Environ Microbiol; 2012 Jan; 78(2):420-8. PubMed ID: 22101049 [TBL] [Abstract][Full Text] [Related]
15. Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. Busquets D; Mas-de-Xaxars T; López-Siles M; Martínez-Medina M; Bahí A; Sàbat M; Louvriex R; Miquel-Cusachs JO; Garcia-Gil JL; Aldeguer X J Crohns Colitis; 2015 Oct; 9(10):899-906. PubMed ID: 26142465 [TBL] [Abstract][Full Text] [Related]
16. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Hansen R; Russell RK; Reiff C; Louis P; McIntosh F; Berry SH; Mukhopadhya I; Bisset WM; Barclay AR; Bishop J; Flynn DM; McGrogan P; Loganathan S; Mahdi G; Flint HJ; El-Omar EM; Hold GL Am J Gastroenterol; 2012 Dec; 107(12):1913-22. PubMed ID: 23044767 [TBL] [Abstract][Full Text] [Related]
17. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? Jia W; Whitehead RN; Griffiths L; Dawson C; Waring RH; Ramsden DB; Hunter JO; Cole JA FEMS Microbiol Lett; 2010 Sep; 310(2):138-44. PubMed ID: 20695899 [TBL] [Abstract][Full Text] [Related]